drugset / Trial / NCT02076529
Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting
RandomizedParallel-groupDouble-blindSupportive care
Summary
This study is designted to know optimal dose of Ramosteron to control for chemotherapy induced nasea and vomoting (CINV)based on its pharmacokinetics, pharmacodynamic study and clinilcal parameters using Rhodes Index.
Timeline
- Start
- 2012-10
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ramosetron | Small molecule | 0.3 mg | — |
| Comparator | Ramosetron | Small molecule | 0.45 mg | — |
| Comparator | Ramosetron | Small molecule | 0.6 mg | — |